Bone Therapeutics celebrates ten years of innovation in bone cell therapy
Gosselies, Belgium, 3 June 2016 – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the fields of bone fracture repair, fracture prevention and spinal fusion, today celebrates its ten-year anniversary with an evening event which will bring together guests from industry, government and the media as well as representatives of the international scientific community. The event will be attended by Mr Paul Magnette, Minister-President of Wallonia and Mr Jean-Claude Marcourt, Vice-President and Minister of Economy, Industry, Innovation and New Technologies of the Walloon Government.
Enrico Bastianelli, Chief Executive Officer of Bone Therapeutics, commented: “We are proud of what we have achieved in the ten years since Bone Therapeutics was founded in 2006. We have come a long way, with two products in the clinic, six clinical trials and preparations underway to initiate trials in the US. We are grateful for the support of our investors, as well as the Walloon Government, without whom this would not have been possible. We want to mark this ten-year milestone in the company’s history, and look forward to the next ten years of progress.”
Paul Magnette, Minister-President of Wallonia and Mayor of Charleroi said: “Bone Therapeutics is a great example of how dynamic, high technology companies enhance the economy and social fabric of Wallonia, creating employment and bringing innovation to the region. Wallonia has established a leadership position in the field of cell therapy in part through the achievements of companies like Bone Therapeutics and their contributions to this endeavour.”
Jean-Claude Marcourt, Vice-President and Minister of Economy, Industry, Innovation and New Technologies of the Walloon Government, adds: “Over the past decade, Wallonia has seen its biotechnology industry grow significantly and it is now at the forefront in the field of cell therapy. An important contributory factor was the creation of Biowin, the health cluster of Wallonia. This initiative, which has a broad international reach, creates the perfect ecosystem for emerging biotech companies to thrive. The Walloon region has supported and keeps on supporting innovative ventures, like Bone Therapeutics, that strengthen its position.”
Since its foundation in 2006 as a spin-off from the Université Libre de Bruxelles (ULB: Brussels, Belgium), Bone Therapeutics has focused on developing a technology initiated at the Erasme Hospital of the ULB. The Company has built on these initial foundations and is now running clinical trials in six indications. With the support of its shareholders and the Walloon Region, the Company has grown significantly over the past ten years, employing over 100 people, and has established its position as a leader in the field of cell therapy.
About Bone Therapeutics
Bone Therapeutics is a leading biotechnology company specializing in the development of cell therapy products intended for bone fracture repair and fracture prevention. The current standard-of-care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative regenerative products containing osteoblastic/bone-forming cells, administrable via a minimally invasive percutaneous technique; a unique proposition in the market.
PREOB®, Bone Therapeutics’ autologous bone cell product, is currently in pivotal Phase IIB/III clinical studies for two indications: osteonecrosis and non-union fractures, and in Phase II for severe osteoporosis. ALLOB®, its allogeneic “off-the-shelf” bone cell product, is in Phase II for the treatment of delayed-union fractures and lumbar fusion for degenerative disease of the spine, including a minimally invasive therapy for failed spinal fusions. The Company also runs preclinical research programs and develops novel product candidates.
Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics’ regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering 11 patent families. Further information is available at: www.bonetherapeutics.com.
